Wire · opportunities
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
FDA approves Freenome's SimpleScreen CRC blood-based colorectal cancer screening test with 81% sensitivity for cancer detection; Abbott gains exclusive US commercialisation rights and receives $100m milestone payment, with Medicare coverage and American Cancer Society guideline inclusion expected.
This Wire brief sits within Fusion42's coverage of Diagnostics. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ ◆ The Wire takeaway
Abbott just acquired Freenome's market position without acquiring Freenome itself - they own the exclusive US route to 60 million unscreened patients via a test that now has Medicare reimbursement and guideline backing. If you make upstream components for blood-based cancer screening (sample collection, lab infrastructure, AI signal processing), Abbott's scale just became your customer.
◆ Related on Wire
◆ Topics